13 High Growth Low PE Stocks to Invest In Now
On August 25, Zeina Bain, managing partner at Sullivan Street Partners, appeared on CNBC to talk about how investors will cycle further into equities following Fed Chair Jerome Powell’s dovish speech...
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,541,181 | $132,192,236 | +128% | 0.09% |
| 2. | 71,000,000 | $70,786,361 | +19% | 4.02% | |
| 3. | 70,000,000 | $69,642,608 | 0.14% | ||
| 4. | 65,000,000 | $64,730,250 | 3.26% | ||
| 5. | 51,500,000 | $58,771,767 | +38% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.83 | 5,052 | $327,511.06 | 733,719 | 2025-08-13 | Filing | |
| $64.15 | 14,948 | $958,839.46 | 738,771 | 2025-08-13 | Filing | |
| $64.00 | 6,958 | $445,318.96 | 733,719 | 2025-08-12 | Filing | |
| $63.24 | 13,042 | $824,802.16 | 740,677 | 2025-08-12 | Filing | |
| $63.60 | 1,283 | $81,596.23 | 733,719 | 2025-08-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,200,032 | $686,665,663 | 0.01% | |
| 2. | 12,245,602 | $637,016,216 | 0.01% | |
| 3. | 5,935,045 | $308,741,041 | 0.01% | |
| 4. | 3,465,889 | $180,295,546 | 0.03% | |
| 5. | 3,397,697 | $176,748,198 | 3.76% |
News See All
Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C.
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Kayla, and I will be your conference operator today.
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to invest in now.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” first quarter 2025 investor letter.
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
